New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 17, 2013
08:04 EDTALNYAlnylam announces proof-of-concept data from RNAi program
Alnylam announced that it has presented pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 for the treatment of porphyria including acute intermittent porphyria. "The new research results support the advancement of RNAi therapeutics as a promising strategy for the prevention and/or treatment of acute attacks in patients with AIP," the company said. It added, "In particular, a prototype GalNAc-siRNA targeting ALAS-1 was shown to be effective in blocking ALA and PBG production in both prophylactic and treatment models of AIP. The company is on track to designate a GalNAc-siRNA development candidate, ALN-AS1, in late 2013 resulting in an investigational new drug (IND) filing in 2014."
News For ALNY From The Last 14 Days
Check below for free stories on ALNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
13:51 EDTALNYAlnylam COO critical of big pharma, FierceDrugDelivery reports
After Novartis (NVS) decided to end its RNAi research, Alnylam COO Barry Greene told FierceDrugDelivery that big pharma has "never been able to innovate." Greene attributes the recent sell-off in Alnylam shares to "generally bearish sentiment on Wall Street regarding biotech stocks in particular." Reference Link
April 15, 2014
07:35 EDTALNYAlnylam outlook not affected by Novartis decision, says JMP Securities
Subscribe for More Information
April 14, 2014
14:42 EDTALNYAlnylam slips after Novartis reportedly cuts back RNAi development
Subscribe for More Information
April 8, 2014
11:03 EDTALNYPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
April 7, 2014
08:09 EDTALNYAlnylam's McSwiggen patent upheld in European opposition proceedings
Subscribe for More Information
07:31 EDTALNYAlnylam shares 'very attractive' at current levels, says Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use